{
  "id": "trips-agreement",
  "title": "Agreement on Trade-Related Aspects of Intellectual Property Rights",
  "lang": "en",
  "source_lang": "en",
  "summary": "The TRIPS Agreement establishes minimum intellectual property standards, enforcement obligations, and dispute-settlement rules for World Trade Organization members.",
  "category": "society",
  "subcategory": "law",
  "type": "work",
  "aliases": [
    "TRIPS Agreement",
    "TRIPS",
    "Agreement on TRIPS"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/trips-agreement/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/trips-agreement/",
      "json": "https://aiwiki.page/zh/trips-agreement.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "The Agreement on Trade-Related Aspects of Intellectual Property Rights, generally known as the TRIPS Agreement, is the principal multilateral agreement establishing minimum standards for the protection and enforcement of intellectual property. It forms Annex 1C of the agreement establishing the World Trade Organization (WTO), which entered into force on 1 January 1995. Its obligations cover copyright, trademarks, geographical indications, industrial designs, patents, integrated-circuit layout designs, and undisclosed information. It also regulates domestic enforcement and makes intellectual property obligations enforceable through the WTO’s interstate dispute-settlement system.\n\nTRIPS brought previously separate areas of intellectual property regulation into a common framework linked to international trade. It requires members to protect specified rights but does not create a worldwide patent, copyright, or trademark, and it leaves significant choices to national legal systems. Its provisions address both the interests of right holders and the public interest in technological dissemination, competition, and access to knowledge and medicines. The relationship between these objectives has shaped its implementation, interpretation, and subsequent amendment."
    },
    {
      "heading": "Negotiation and incorporation into the trading system",
      "text": "Before TRIPS, international intellectual property protection rested chiefly on specialized treaties, particularly the Paris Convention for the Protection of Industrial Property of 1883 and the Berne Convention for the Protection of Literary and Artistic Works of 1886. These agreements established national-treatment obligations and substantive protections, but they did not provide the combination of detailed enforcement standards and trade-related dispute settlement later incorporated into TRIPS. Their administration became a central function of the World Intellectual Property Organization (WIPO).\n\nDuring the 1970s and 1980s, the increasing importance of pharmaceuticals, software, entertainment, and branded goods made differences between national intellectual property systems more prominent in trade policy. Businesses in several industrialized economies sought stronger protection against unauthorized copying, counterfeiting, and the commercial use of inventions abroad. Developing countries expressed concerns about technology costs, the scope of national industrial policy, and the suitability of trade negotiations for setting intellectual property standards. Negotiating positions nevertheless varied considerably within both groups.\n\nThe negotiations took place during the Uruguay Round, launched in September 1986 under the General Agreement on Tariffs and Trade (GATT). The negotiating mandate addressed trade-related intellectual property issues, including trade in counterfeit goods. Discussions eventually extended well beyond border counterfeiting to substantive standards across the principal categories of intellectual property. A comprehensive draft appeared in the December 1991 negotiating text associated with GATT Director-General Arthur Dunkel and provided much of the basis for the final agreement.\n\nTRIPS was concluded as part of the Marrakesh package signed on 15 April 1994. Its position within that package was consequential: participation in the WTO generally required acceptance of the multilateral agreements in its principal annexes rather than selective adherence to individual intellectual property obligations. TRIPS therefore reached a wider and more economically diverse membership than would likely have joined an independent agreement containing the same standards.\n\nThe agreement did not replace WIPO or the earlier conventions. Instead, it incorporated or supplemented important parts of existing treaty law and added WTO supervision and dispute settlement. A WTO–WIPO cooperation agreement, effective in 1996, established arrangements concerning notifications, legal information, and technical assistance. The resulting institutional structure divides responsibilities: WIPO continues to administer specialized intellectual property treaties and international filing systems, while the WTO supervises compliance with TRIPS obligations."
    },
    {
      "heading": "Legal structure and governing principles",
      "text": "TRIPS contains 73 articles arranged in seven parts. These cover general principles, substantive standards, enforcement, acquisition and maintenance of rights, dispute prevention and settlement, transitional arrangements, and institutional provisions. Article 1.1 permits members to provide more extensive protection than TRIPS requires, provided that it does not contravene the agreement. Members also remain free to choose the appropriate method of implementation within their legal systems. Consequently, compliance does not require identical statutes, administrative procedures, or judicial institutions.\n\nTwo nondiscrimination rules underpin the agreement. Article 3 establishes national treatment: subject to specified exceptions, members must treat other members’ nationals no less favourably than their own nationals concerning intellectual property protection. Article 4 establishes most-favoured-nation treatment: an advantage granted to the nationals of one country generally must be extended immediately and unconditionally to the nationals of all WTO members. Exceptions exist, including for certain international agreements and forms of judicial assistance.\n\nArticles 7 and 8 articulate objectives and principles that inform interpretation. Article 7 states that protection and enforcement should contribute to technological innovation and the transfer and dissemination of technology, to the mutual advantage of producers and users of technological knowledge, and to social and economic welfare. Article 8 recognizes that members may adopt measures necessary to protect public health and nutrition and to promote the public interest in sectors vital to socioeconomic and technological development, provided those measures are consistent with the agreement. These provisions do not create an unrestricted exemption, but they establish that private exclusivity is not the agreement’s sole purpose.\n\nTRIPS generally leaves rights territorial. A patent granted in one jurisdiction does not automatically become enforceable in another, and infringement is ordinarily assessed under the applicable domestic law. Nor does TRIPS normally give private parties a direct right to bring proceedings before the WTO. Whether particular treaty provisions can be invoked directly in domestic litigation depends on the constitutional and legal arrangements of the member concerned.\n\nArticle 6 addresses exhaustion: the point at which a right holder’s control over further distribution of a particular product ends after an authorized sale. Subject to national treatment and most-favoured-nation treatment, TRIPS leaves members substantial freedom to choose national, regional, or international exhaustion regimes. That choice affects parallel imports—genuine goods imported outside the right holder’s preferred distribution channels. International exhaustion can permit such imports following an authorized foreign sale; national exhaustion can preserve the right holder’s ability to oppose them. TRIPS therefore establishes common obligations without eliminating important differences in market organization."
    },
    {
      "heading": "Copyright and related rights",
      "text": "For copyright, TRIPS largely builds upon the Berne Convention. Article 9.1 requires compliance with Articles 1–21 of Berne and its appendix, while excluding obligations under TRIPS concerning the moral rights protected by Berne Article 6bis. This does not abolish moral rights or remove obligations arising independently under Berne. It means that those rights are outside the copyright obligations incorporated into the WTO agreement.\n\nArticle 9.2 states the distinction between expression and underlying subject matter: copyright protection extends to expressions, not to ideas, procedures, methods of operation, or mathematical concepts as such. Article 10 expressly requires computer programs, whether in source or object code, to be protected as literary works. It also protects compilations of data or other material when the selection or arrangement constitutes an intellectual creation. This protection does not extend to the data themselves and does not prejudice copyright that may subsist in individual components.\n\nThese rules helped establish an international baseline for software and database protection without requiring a separate proprietary right in raw information. A program’s code may qualify for copyright, while the functional method embodied in the program is not protected merely because that method is expressed in code. Similarly, an original arrangement of information may be protected even where the underlying facts remain available for use. Questions about particular interfaces, structures, or functional elements still depend on domestic law and the applicable treaty standards.\n\nArticle 11 requires commercial rental rights for computer programs and, under specified conditions, cinematographic works. Article 14 establishes minimum protections for performers, producers of phonograms, and broadcasting organizations, with different rights and terms for each category. For example, performers and phonogram producers generally receive protection for at least 50 years calculated from the relevant fixation or performance, while the minimum term for broadcasting organizations is 20 years. TRIPS does not require every member to organize these protections through an identical system of neighbouring rights.\n\nLimitations and exceptions are governed by Article 13’s three-step test. They must be confined to certain special cases, must not conflict with normal exploitation of the work, and must not unreasonably prejudice the legitimate interests of the right holder. The agreement does not prescribe a single model such as enumerated exceptions or fair use. Domestic systems may use different structures, but their operation must satisfy the international standard. In the 2000 dispute concerning section 110(5) of the United States Copyright Act, a WTO panel applied the test to exemptions allowing certain businesses to play radio and television broadcasts without authorization, demonstrating that copyright exceptions could be scrutinized through trade dispute settlement."
    },
    {
      "heading": "Trademarks, geographical indications, and industrial designs",
      "text": "TRIPS establishes standards for several rights that identify commercial origin or protect product appearance. Under Article 15, a trademark may consist of any sign, or combination of signs, capable of distinguishing one undertaking’s goods or services from those of others. Examples include words, names, letters, numerals, figurative elements, and colour combinations. Members may make registration dependent on distinctiveness acquired through use and may require signs to be visually perceptible. The agreement therefore does not mandate identical treatment of sound, scent, and other nontraditional marks.\n\nArticle 16 gives the owner of a registered trademark the right to prevent unauthorized use of identical or similar signs for identical or similar goods or services where confusion is likely. Confusion is presumed when both the sign and the goods or services are identical. TRIPS also strengthens protection for well-known marks by extending relevant Paris Convention principles to services and, under specified conditions, to dissimilar goods or services. Registrations and renewals must last at least seven years, and registration must be renewable indefinitely. Where use is required to maintain registration, cancellation for non-use ordinarily cannot occur until at least three uninterrupted years have passed, unless valid reasons justify the absence of use.\n\nA geographical indication identifies a good as originating in a territory, region, or locality where a quality, reputation, or other characteristic is essentially attributable to geographical origin. Article 22 requires legal means to prevent misleading uses and uses constituting unfair competition. Article 23 provides additional protection for wines and spirits, including against certain uses accompanied by expressions such as “kind,” “type,” or “imitation,” even without proof that consumers are misled. Article 24 contains exceptions and negotiating provisions addressing matters such as prior trademarks, customary names, and certain earlier uses.\n\nThe agreement does not require geographical indications to be protected through one particular legal form. Members may rely on dedicated registration systems, certification or collective marks, unfair-competition rules, or combinations of mechanisms. Disagreements have concerned the extent of additional protection and its relationship with trademarks. In disputes concerning the European Communities’ geographical-indication system, reports adopted in 2005 examined national treatment, registration procedures, and coexistence with earlier trademarks rather than requiring all members to adopt the same model.\n\nFor industrial designs, Articles 25 and 26 require protection for independently created designs that are new or original. Members need not protect designs dictated essentially by technical or functional considerations. Protection must extend for at least ten years and generally allows the right holder to prevent commercial manufacture, sale, or importation of articles bearing a copy, or substantially a copy, of the protected design. Special attention is given to textile designs: the cost, examination, or publication requirements for obtaining protection must not unreasonably impair the opportunity to seek it."
    },
    {
      "heading": "Patent standards and permitted exceptions",
      "text": "The patent provisions produced some of TRIPS’s most substantial changes to national law. Article 27.1 generally requires patents to be available for inventions in all fields of technology, whether products or processes, provided they are new, involve an inventive step, and are capable of industrial application. Patent availability and enjoyment of patent rights must generally be nondiscriminatory concerning the place of invention, the technological field, and whether products are imported or locally produced. This limited the ability to exclude entire industries, such as pharmaceuticals, from product patent protection.\n\nArticle 28 specifies the core exclusive rights. For a product patent, the owner must be able to prevent unauthorized making, using, offering for sale, selling, or importing for those purposes. For a process patent, protection extends both to use of the process and to specified dealings in products obtained directly by it. Article 33 requires a term of at least 20 years from the filing date. This is a minimum patent term, not a guarantee of 20 years of commercial exclusivity after marketing authorization or product launch.\n\nPatent applicants must disclose inventions sufficiently clearly and completely for a person skilled in the art to carry them out. Under Article 29, members may also require disclosure of the best mode known to the inventor. These disclosure requirements reflect the exchange underlying patent protection: temporary exclusion is accompanied by the publication of technical knowledge. TRIPS does not, however, fully harmonize examination standards, the interpretation of patent claims, or the assessment of particular inventions.\n\nArticle 27 permits specified exclusions. Members may exclude inventions where preventing their commercial exploitation is necessary to protect public order or morality, including human, animal, or plant life or health, or to avoid serious environmental prejudice. They may also exclude diagnostic, therapeutic, and surgical methods for treating humans or animals. Plants and animals other than microorganisms, and essentially biological processes other than nonbiological and microbiological processes, may be excluded. Plant varieties must nevertheless receive protection through patents, an effective special system, or a combination of the two.\n\nArticles 30 and 31 regulate uses without ordinary authorization. Article 30 permits limited exceptions satisfying a three-part standard concerning the normal exploitation of the patent and the legitimate interests of the patent owner and third parties. Article 31 permits compulsory licensing and government use subject to conditions including individual consideration, appropriate scope and duration, adequate remuneration, and review. Prior efforts to obtain a voluntary licence on reasonable commercial terms are generally required, but may be waived for national emergencies, extreme urgency, or public noncommercial use. Compulsory licensing is therefore not confined to emergencies; emergencies affect particular procedural requirements."
    },
    {
      "heading": "Undisclosed information, technological knowledge, and competition",
      "text": "Article 39 requires protection of undisclosed information against specified forms of unfair commercial conduct. Information qualifies when it is secret in the sense that it is not generally known or readily accessible within relevant circles, has commercial value because it is secret, and has been subject to reasonable steps to keep it secret. The obligation concerns acquisition, disclosure, or use without consent in a manner contrary to honest commercial practices, including breach of confidence and inducement to breach.\n\nUnlike a patent, this protection does not depend on publication or a fixed term of exclusivity. It also does not create an absolute right against everyone who independently obtains the same knowledge. Independent discovery is not equivalent to misappropriation, and TRIPS does not generally transform trade secrecy into patent-like protection against all use of the information. The interaction between confidentiality obligations, employee mobility, reverse engineering, and evidence remains substantially dependent on domestic implementation.\n\nArticle 39.3 separately addresses regulatory submissions. Where members require undisclosed test or other data to approve pharmaceutical or agricultural chemical products using new chemical entities, and the generation of those data involves considerable effort, they must protect them against unfair commercial use. They must also protect against disclosure, subject to stated public-protection exceptions. The text does not expressly prescribe a fixed period of exclusive reliance on such data. The relationship between this obligation and domestic regulatory reliance on an earlier applicant’s evidence has therefore been a significant interpretive and policy issue.\n\nIntegrated-circuit layout designs receive protection under Articles 35–38, which incorporate specified provisions of the 1989 Washington Treaty on Intellectual Property in Respect of Integrated Circuits. TRIPS regulates unauthorized reproduction and commercial dealings in protected layouts and chips incorporating them. It also provides special treatment for innocent acquisition and limits on compulsory licensing. Protection must generally last at least ten years under the applicable registration- or exploitation-based arrangements, with an optional outer limit of 15 years from creation.\n\nThe agreement also recognizes that intellectual property practices may restrict competition. Article 40 permits members to identify and control abusive licensing practices, with examples including exclusive grant-back conditions, conditions preventing challenges to validity, and coercive package licensing. It provides for consultations between members when relevant conduct crosses borders. Articles 7 and 8 supply a broader framework connecting protection with dissemination and the prevention of abuse. These provisions do not harmonize competition law or require every restrictive licence to be treated alike; rather, they preserve room for competition measures consistent with the agreement."
    },
    {
      "heading": "Domestic enforcement and procedural safeguards",
      "text": "Part III of TRIPS establishes minimum standards for enforcing rights through domestic institutions. Article 41 requires procedures permitting effective action against infringement, including expeditious remedies and remedies that deter further violations. At the same time, procedures must avoid barriers to legitimate trade and include safeguards against abuse. They must be fair and equitable, must not be unnecessarily complicated or costly, and must not involve unreasonable time limits or unwarranted delays.\n\nCivil and administrative procedures must provide specified protections associated with due process. Defendants must receive timely and sufficiently detailed notice, parties must have opportunities to substantiate their claims, and confidential information must receive protection. Judicial authorities must possess powers concerning production of evidence, injunctions, and damages. Compensation is required where an infringer knowingly, or with reasonable grounds to know, engaged in infringement; the agreement also addresses recovery of expenses and other remedies. In process-patent disputes, Article 34 requires mechanisms that can shift the evidentiary burden under specified circumstances, reflecting the difficulty of proving how an imported product was manufactured.\n\nArticle 50 requires provisional measures to prevent infringement and preserve relevant evidence. In appropriate cases, authorities must be able to act without first hearing the other party, especially where delay could cause irreparable harm or evidence might be destroyed. This power is balanced by requirements concerning evidence, security, prompt notice, review, and possible compensation when measures prove unjustified. Provisional enforcement is therefore not an unconditional entitlement to seize goods or interrupt a competitor’s business.\n\nThe border-measures provisions require procedures through which right holders can seek suspension of the release of imported counterfeit trademark goods and pirated copyright goods. Members may extend such procedures to additional forms of infringement and to other customs situations, but the mandatory scope is narrower than the full range of intellectual property. The rules include safeguards concerning applications, security, notification, deadlines, and wrongful detention. Members may exclude small quantities of noncommercial goods in travellers’ personal luggage or small consignments.\n\nArticle 61 requires criminal procedures and penalties at least for wilful trademark counterfeiting or copyright piracy on a commercial scale. It does not require criminal penalties for every patent dispute or every unauthorized use of protected material. Article 41.5 further specifies that members need not establish a judicial system separate from ordinary law enforcement, and it disclaims obligations concerning the distribution of resources between intellectual property enforcement and law enforcement generally. These limits distinguish minimum enforcement capacity from an obligation to give intellectual property claims unlimited institutional priority."
    },
    {
      "heading": "Public health, compulsory licensing, and the Article 31bis system",
      "text": "The interaction between pharmaceutical patents and access to medicines became a central issue in the late 1990s and early 2000s. The HIV/AIDS crisis made the cost and availability of treatment particularly prominent, while WTO members disagreed about how the agreement’s safeguards should operate. On 14 November 2001, ministers adopted the Doha Declaration on the TRIPS Agreement and Public Health. It affirmed that TRIPS can and should be interpreted and implemented in a manner supportive of members’ right to protect public health and promote access to medicines for all.\n\nThe declaration confirmed that each member may grant compulsory licences and determine the grounds on which they are granted. It also confirmed members’ freedom to determine what constitutes a national emergency or other circumstance of extreme urgency, recognizing that public health crises including HIV/AIDS, tuberculosis, malaria, and other epidemics can qualify. These statements clarified the interpretation of existing provisions; they did not make an emergency a prerequisite for every compulsory licence or automatically suspend pharmaceutical patents.\n\nA separate difficulty concerned countries lacking sufficient pharmaceutical manufacturing capacity. Article 31(f) originally required production under a compulsory licence to be predominantly for the domestic market of the authorizing member. This constrained the ability of an exporting country to manufacture primarily for an importing country that could not make the medicine itself. The declaration’s paragraph 6 directed the WTO to find an expeditious solution.\n\nA General Council decision of 30 August 2003 established a waiver mechanism for eligible pharmaceutical exports. A protocol adopted on 6 December 2005 subsequently provided for a permanent amendment, which entered into force on 23 January 2017 for members accepting it. The resulting Article 31bis system allows qualifying exports under compulsory licences, subject to notification and safeguards. These include identification of needed products and quantities, measures against diversion, and differentiated identification of exported products where feasible. Canada’s authorization of exports of an antiretroviral medicine to Rwanda, followed by shipments in 2008 and 2009, became the principal early example of the mechanism in operation.\n\nOn 17 June 2022, the WTO Ministerial Conference adopted a further decision concerning the production and supply of COVID-19 vaccines by eligible developing-country members. For five years from that date, it permits specified departures from or clarifications of ordinary Article 31 requirements, including the domestic-market restriction, for the covered subject matter. It was not a blanket suspension of all intellectual property rights or an automatic authorization covering every COVID-19-related product. The vaccine-specific decision illustrates the distinction between a targeted WTO decision and a general amendment of the substantive intellectual property system."
    },
    {
      "heading": "Implementation periods, development, and technology transfer",
      "text": "TRIPS implementation was staggered according to members’ circumstances. Article 65 provided a general one-year transition after the WTO’s entry into force, making most obligations applicable to developed-country members from 1 January 1996. Developing-country members generally received an additional four years, until 1 January 2000, while national treatment and most-favoured-nation treatment were subject to the shorter timetable. Certain economies undergoing transition from centrally planned systems could also use the additional period where the specified conditions applied.\n\nDeveloping countries that had not previously provided product patent protection in particular technological fields could delay those obligations for an additional five years, until 1 January 2005. Special interim arrangements nevertheless applied to pharmaceutical and agricultural chemical products. Article 70.8 required a system for receiving patent applications—the “mailbox” mechanism—so that qualifying applications could later be examined while preserving their filing or priority dates. Article 70.9 required limited exclusive marketing rights where its conditions were met. These were specific transitional duties, not an immediate general requirement to grant full pharmaceutical product patents.\n\nLeast-developed-country members received separate treatment under Article 66.1. A June 2021 TRIPS Council decision extended their general transition until 1 July 2034, or until they cease to be least-developed countries, whichever occurs first. A separate 2015 decision provides a pharmaceutical-related transition until 1 January 2033, likewise subject to earlier graduation, accompanied by related waivers. These arrangements do not mean that least-developed countries lack domestic intellectual property systems; rather, they postpone specified WTO obligations and preserve policy choices during the transition.\n\nArticle 66.2 obliges developed-country members to provide incentives to enterprises and institutions in their territories to promote and encourage technology transfer to least-developed-country members. The aim is to enable the creation of a sound and viable technological base. Reporting and review procedures allow the TRIPS Council to examine implementation. This obligation is distinct from a duty to compel a private firm to transfer any particular patent or manufacturing process, and the agreement does not guarantee a predetermined volume of technology transfer.\n\nArticle 67 addresses technical and financial cooperation for developing and least-developed members on request and on mutually agreed terms. Assistance may concern legislation, enforcement, administrative institutions, and training. Implementation consequently involves more than adopting statutes: patent examination capacity, judicial expertise, regulatory institutions, and the ability of local firms to absorb knowledge affect how the rules operate. Economic research distinguishes the legal strength of protection from these broader institutional and industrial conditions, making the effects of TRIPS dependent on country, sector, and technological capacity rather than a single uniform outcome."
    },
    {
      "heading": "WTO supervision, disputes, and the limits of harmonization",
      "text": "The Council for TRIPS supervises the agreement’s operation, reviews implementation, provides a forum for consultations, and performs responsibilities assigned by the agreement or WTO bodies. Members notify relevant laws and regulations under Article 63, allowing other members to examine how obligations are implemented. Article 64 connects TRIPS to the WTO dispute-settlement system. Disputes are brought by members against other members, not directly by companies against foreign governments. The usual objective is to bring an inconsistent measure into conformity; WTO remedies do not ordinarily award damages to an affected patent holder or author.\n\nEarly disputes established that transitional provisions could impose enforceable obligations even before all substantive patent rules became applicable. In India—Patent Protection for Pharmaceutical and Agricultural Chemical Products, reports adopted in 1998 examined India’s mailbox arrangements and exclusive marketing rights. In Canada—Patent Protection of Pharmaceutical Products, a panel report adopted in 2000 distinguished a regulatory-review exception, which it upheld under Article 30, from a stockpiling exception, which it found inconsistent. The distinction showed that access-related exceptions are assessed through their legal design and effects rather than being automatically permitted or prohibited.\n\nLater disputes addressed enforcement, branding, and public regulation. A report adopted in 2009 in China—Measures Affecting the Protection and Enforcement of Intellectual Property Rights examined criminal thresholds, disposal of infringing goods, and copyright protection. The disputes over Australian tobacco plain packaging considered whether standardized packaging requirements breached, among other provisions, trademark-related TRIPS obligations. Panel reports issued in 2018 and Appellate Body reports adopted in 2020 rejected the claims pursued against the measures. Their treatment of trademark rights distinguished rights to prevent unauthorized third-party uses from an unrestricted entitlement to use a mark free of regulation.\n\nTRIPS establishes a floor rather than complete harmonization. Many bilateral and regional agreements contain “TRIPS-plus” commitments, such as longer protection, patent-term adjustments, regulatory data exclusivity, or additional enforcement requirements. Their legal source is the separate agreement, not TRIPS itself. The distinction matters when assessing whether a particular domestic rule is required by the WTO, adopted voluntarily, or owed under another treaty.\n\nOther issues remain subjects of negotiation and institutional discussion. These include the relationship between patents, biodiversity, and traditional knowledge; additional protection for geographical indications; and the treatment of intellectual property in digital environments. A WIPO treaty adopted in May 2024 concerning intellectual property, genetic resources, and associated traditional knowledge created a separate framework for patent-disclosure requirements under specified circumstances; its adoption did not itself amend TRIPS. Similarly, questions surrounding artificial intelligence, digital copying, and new licensing practices are evaluated through existing treaty categories and domestic law unless members agree on additional international rules."
    }
  ],
  "links": [
    "intellectual-property",
    "world-trade-organization",
    "trade",
    "treaty",
    "paris-convention",
    "berne-convention",
    "world-intellectual-property-organization",
    "uruguay-round",
    "general-agreement-on-tariffs-and-trade",
    "national-treatment",
    "most-favoured-nation-treatment",
    "copyright",
    "moral-rights",
    "fair-use",
    "trademark",
    "geographical-indication",
    "industrial-design",
    "patent",
    "inventive-step",
    "patent-claim",
    "compulsory-license",
    "trade-secret",
    "competition-law",
    "due-process",
    "injunction",
    "damages",
    "public-health",
    "biodiversity",
    "traditional-knowledge",
    "artificial-intelligence"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}